vs
基华物流（CEVA）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
基华物流的季度营收约是REGENXBIO Inc.的1.0倍（$31.3M vs $30.3M），基华物流净利率更高（-3.5% vs -221.3%，领先217.8%），REGENXBIO Inc.同比增速更快（43.0% vs 7.1%），基华物流自由现金流更多（$7.2M vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs 19.1%）
赛物流是一家全球物流与供应链企业，提供货运管理以及合约物流服务，2019年被达飞海运集团收购。收购完成后，达飞集团陆续将英格迈微商务生命周期服务、GEFCO等多家物流运输企业并入赛物流，助力其业务发展与规模扩张。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
CEVA vs RGNX — 直观对比
营收规模更大
CEVA
是对方的1.0倍
$30.3M
营收增速更快
RGNX
高出35.9%
7.1%
净利率更高
CEVA
高出217.8%
-221.3%
自由现金流更多
CEVA
多$60.0M
$-52.8M
两年增速更快
RGNX
近两年复合增速
19.1%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $31.3M | $30.3M |
| 净利润 | $-1.1M | $-67.1M |
| 毛利率 | 88.1% | — |
| 营业利润率 | -1.3% | -190.0% |
| 净利率 | -3.5% | -221.3% |
| 营收同比 | 7.1% | 43.0% |
| 净利润同比 | 36.8% | -31.2% |
| 每股收益（稀释后） | — | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CEVARGNX
| Q4 25 | $31.3M | $30.3M | ||
| Q3 25 | $28.4M | $29.7M | ||
| Q2 25 | $25.7M | $21.4M | ||
| Q1 25 | $24.2M | $89.0M | ||
| Q4 24 | $29.2M | $21.2M | ||
| Q3 24 | $27.2M | $24.2M | ||
| Q2 24 | $28.4M | $22.3M | ||
| Q1 24 | $22.1M | $15.6M |
净利润CEVARGNX
| Q4 25 | $-1.1M | $-67.1M | ||
| Q3 25 | $-2.5M | $-61.9M | ||
| Q2 25 | $-3.7M | $-70.9M | ||
| Q1 25 | $-3.3M | $6.1M | ||
| Q4 24 | $-1.7M | $-51.2M | ||
| Q3 24 | $-1.3M | $-59.6M | ||
| Q2 24 | $-291.0K | $-53.0M | ||
| Q1 24 | $-5.4M | $-63.3M |
毛利率CEVARGNX
| Q4 25 | 88.1% | — | ||
| Q3 25 | 88.0% | — | ||
| Q2 25 | 86.2% | — | ||
| Q1 25 | 85.6% | — | ||
| Q4 24 | 88.5% | 70.2% | ||
| Q3 24 | 85.4% | 48.8% | ||
| Q2 24 | 89.7% | 52.5% | ||
| Q1 24 | 88.7% | 72.6% |
营业利润率CEVARGNX
| Q4 25 | -1.3% | -190.0% | ||
| Q3 25 | -7.3% | -176.3% | ||
| Q2 25 | -17.5% | -296.3% | ||
| Q1 25 | -18.1% | 13.6% | ||
| Q4 24 | 0.3% | -242.1% | ||
| Q3 24 | -9.6% | -256.6% | ||
| Q2 24 | -0.1% | -251.3% | ||
| Q1 24 | -22.5% | -408.8% |
净利率CEVARGNX
| Q4 25 | -3.5% | -221.3% | ||
| Q3 25 | -8.8% | -208.3% | ||
| Q2 25 | -14.4% | -331.8% | ||
| Q1 25 | -13.7% | 6.8% | ||
| Q4 24 | -5.9% | -241.3% | ||
| Q3 24 | -4.8% | -246.3% | ||
| Q2 24 | -1.0% | -237.7% | ||
| Q1 24 | -24.7% | -405.4% |
每股收益（稀释后）CEVARGNX
| Q4 25 | — | $-1.30 | ||
| Q3 25 | — | $-1.20 | ||
| Q2 25 | — | $-1.38 | ||
| Q1 25 | — | $0.12 | ||
| Q4 24 | — | $-0.99 | ||
| Q3 24 | — | $-1.17 | ||
| Q2 24 | — | $-1.05 | ||
| Q1 24 | — | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $40.6M | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $336.5M | $102.7M |
| 总资产 | $388.3M | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CEVARGNX
| Q4 25 | $40.6M | $230.1M | ||
| Q3 25 | $17.3M | $274.2M | ||
| Q2 25 | $29.1M | $323.3M | ||
| Q1 25 | $18.8M | $267.9M | ||
| Q4 24 | $18.8M | $234.7M | ||
| Q3 24 | $13.2M | $255.5M | ||
| Q2 24 | $25.0M | $290.4M | ||
| Q1 24 | $21.6M | $338.7M |
股东权益CEVARGNX
| Q4 25 | $336.5M | $102.7M | ||
| Q3 25 | $268.7M | $161.5M | ||
| Q2 25 | $265.9M | $213.7M | ||
| Q1 25 | $269.1M | $274.2M | ||
| Q4 24 | $266.6M | $259.7M | ||
| Q3 24 | $265.8M | $301.4M | ||
| Q2 24 | $263.8M | $348.3M | ||
| Q1 24 | $262.3M | $390.7M |
总资产CEVARGNX
| Q4 25 | $388.3M | $453.0M | ||
| Q3 25 | $306.0M | $525.2M | ||
| Q2 25 | $302.8M | $581.0M | ||
| Q1 25 | $310.0M | $490.9M | ||
| Q4 24 | $308.9M | $466.0M | ||
| Q3 24 | $304.9M | $519.1M | ||
| Q2 24 | $300.4M | $569.4M | ||
| Q1 24 | $301.4M | $629.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $8.7M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $7.2M | $-52.8M |
| 自由现金流率自由现金流/营收 | 23.1% | -174.0% |
| 资本支出强度资本支出/营收 | 4.8% | 1.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-6.3M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流CEVARGNX
| Q4 25 | $8.7M | $-52.3M | ||
| Q3 25 | $-5.9M | $-56.0M | ||
| Q2 25 | $1.2M | $-49.3M | ||
| Q1 25 | $-7.4M | $33.6M | ||
| Q4 24 | $8.0M | $-31.6M | ||
| Q3 24 | $399.0K | $-40.5M | ||
| Q2 24 | $2.4M | $-45.5M | ||
| Q1 24 | $-7.3M | $-55.5M |
自由现金流CEVARGNX
| Q4 25 | $7.2M | $-52.8M | ||
| Q3 25 | $-6.3M | $-56.5M | ||
| Q2 25 | $492.0K | $-49.7M | ||
| Q1 25 | $-7.7M | $32.6M | ||
| Q4 24 | $7.0M | $-32.7M | ||
| Q3 24 | $-15.0K | $-40.9M | ||
| Q2 24 | $1.8M | $-46.0M | ||
| Q1 24 | $-8.3M | $-56.0M |
自由现金流率CEVARGNX
| Q4 25 | 23.1% | -174.0% | ||
| Q3 25 | -22.1% | -189.9% | ||
| Q2 25 | 1.9% | -232.8% | ||
| Q1 25 | -31.8% | 36.6% | ||
| Q4 24 | 24.0% | -154.2% | ||
| Q3 24 | -0.1% | -168.9% | ||
| Q2 24 | 6.2% | -206.2% | ||
| Q1 24 | -37.4% | -358.5% |
资本支出强度CEVARGNX
| Q4 25 | 4.8% | 1.7% | ||
| Q3 25 | 1.5% | 1.7% | ||
| Q2 25 | 2.7% | 1.8% | ||
| Q1 25 | 1.3% | 1.2% | ||
| Q4 24 | 3.5% | 5.1% | ||
| Q3 24 | 1.5% | 1.3% | ||
| Q2 24 | 2.1% | 2.1% | ||
| Q1 24 | 4.1% | 3.6% |
现金转化率CEVARGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 5.53× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CEVA
| Transferred At Point In Time | $28.1M | 90% |
| Transferred Over Time | $3.2M | 10% |
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
